Previous Article | Next Article 
Infection and Immunity, May 2004, p. 2731-2737, Vol. 72, No. 5
0019-9567/04/$08.00+0 DOI: 10.1128/IAI.72.5.2731-2737.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Enhanced Mucosal Delivery of Antigen with Cell Wall Mutants of Lactic Acid Bacteria
Corinne Grangette,1* Heide Müller-Alouf,1 Pascal Hols,2 Denise Goudercourt,1 Jean Delcour,2 Mireille Turneer,3 and Annick Mercenier1,
Laboratoire de Bactériologie des Ecosytèmes, Institut Pasteur de Lille-Institut de Biologie de Lille, 59019 Lille Cedex, France,1
Unité de Génétique, Université catholique de Louvain, B-1348 Louvain-la-Neuve,2
Laboratoire du Tétanos, Institut Pasteur de Bruxelles, B-1180 Brussels, Belgium3
Received 6 November 2003/
Returned for modification 23 December 2003/
Accepted 5 February 2004

ABSTRACT
The potential of recombinant lactic acid bacteria (LAB) to deliver
heterologous antigens to the immune system and to induce protective
immunity has been best demonstrated by using the C subunit of
tetanus toxin (TTFC) as a model antigen. Two types of LAB carriers
have mainly been used,
Lactobacillus plantarum and
Lactococcus lactis, which differ substantially in their abilities to resist
passage through the stomach and to persist in the mouse gastrointestinal
tract. Here we analyzed the effect of a deficiency in alanine
racemase, an enzyme that participates in cell wall synthesis,
in each of these bacterial carriers. Recombinant wild-type and
mutant strains of
L. plantarum NCIMB8826 and
L. lactis MG1363
producing TTFC intracellularly were constructed and used in
mouse immunization experiments. Remarkably, we observed that
the two cell wall mutant strains were far more immunogenic than
their wild-type counterparts when the intragastric route was
used. However, intestinal TTFC-specific immunoglobulin A was
induced only after immunization with the recombinant
L. plantarum mutant strain. Moreover, the alanine racemase mutant of either
LAB strain allowed induction of a much stronger serum TTFC-specific
immune response after immunization via the vagina, which is
a quite different ecosystem than the gastrointestinal tract.
The design and use of these mutants thus resulted in a major
improvement in the mucosal delivery of antigens exhibiting vaccine
properties.

INTRODUCTION
One of the current goals in vaccine development is induction
of mucosal and systemic responses against protective antigens
delivered by mucosal routes. Live vaccines represent a promising
approach in this area. Most of the systems currently under development
involve pathogenic microorganisms for which attenuated variants
have to be isolated or constructed (
1,
5,
13,
15,
19,
27). Nonpathogenic
food-grade gram-positive bacteria (i.e., lactic acid bacteria
[LAB]) represent an attractive alternative to this end. The
potential of these organisms to deliver heterologous antigens
to the mucosal immune system has been investigated during the
last decade, and the most complete studies have been performed
with tetanus toxin fragment C (TTFC) as a model antigen (
7,
8,
17,
18,
21,
25,
26,
28). We and other workers have previously
shown that TTFC can be efficiently produced in a variety of
LAB strains, including
Lactococcus lactis (
21,
26),
Streptococcus gordonii, and
Lactobacillus spp. (
7,
8,
17,
18,
25,
28). The
best recombinant strains resulted in induction of local and
protective systemic antibody responses, as well as cellular
immune responses, after parenteral or intranasal administration
to mice (
7,
8,
21). In the case of lactobacilli, the amount
of cytoplasmic antigen was found to be critical for induction
of a significant immune response by the oral route (
7). Indeed,
a protective immunoglobulin G (IgG)-mediated response was obtained
when mice were immunized with the
Lactobacillus plantarum NCIMB8826
strain producing large amounts of TTFC intracellularly, whereas
the equivalent strain producing only moderate amounts of antigen
proved to be inefficient (
7). However, both strains exhibited
elevated immunogenicity when they were administered by the nasal
route (
8). High levels of intracellular expression might be
an important bottleneck depending on the nature of the heterologous
polypeptide. We therefore examined whether developing mutant
bacterial carriers could enhance the potential of LAB as a delivery
system. The approach which we decided to pursue was to try to
increase the in vivo release of the cytoplasmic antigen by interfering
with cell wall biosynthesis. By analogy to the work described
for
Bacillus subtilis (
9), we exploited alanine racemase (
alr)
mutants. This enzyme interconverts
L-alanine and
D-alanine and
provides the main biosynthesis pathway for
D-alanine, which
is an essential molecule in the construction of the two major
cell wall polymers of gram-positive bacteria, peptidoglycan
and teichoic acids (
22). Alr-deficient (Alr
) mutants
have been constructed for both
L. plantarum NCIMB8826 (
10) and
L. lactis MG1363 (
11). These mutants are unable to grow in the
absence of
D-alanine, and a lack of this amino acid in the growth
medium leads to cells that have a severely altered cell wall
structure (
22a).
L. plantarum and
L. lactis differ substantially
with respect to the ability to survive in the gastrointestinal
tracts of rodents (
4) and humans (
14,
30), and
L. plantarum is much more resistant to the harsh conditions encountered in
the stomach and the upper part of the intestine. We hypothesized
that the greater and longer persistence of
L. plantarum, while
conferring interesting pharmacokinetic properties to this carrier
(
30), may also lead to sequestration of intracellular bioactive
molecules. In this case, cell wall mutants should perform better
as antigen carriers when the oral route is used. We therefore
constructed recombinant strains producing TTFC intracellularly
in either an
L. plantarum or
L. lactis Alr
background
and compared their immunogenicities to those of the corresponding
wild-type (WT) strains after intragastric administration to
mice. The potential of the Alr
recombinant LAB strains
was further investigated by immunizing mice intravaginally,
taking into consideration the fact that the vagina of mice is
recognized as a poor immune inductive site (
29) and is an ecosystem
that is much different than the intestine.

MATERIALS AND METHODS
Bacterial strains, growth conditions, and preparation of bacterial inocula.
All LAB strains and plasmids used in this study are listed in
Table
1. The recombinant wild-type (rWT)
L. plantarum and
L. lactis strains have been described previously (
7,
8). The plasmid
constructs were introduced by electroporation into the appropriate
Alr
mutants (MD007, MD007Int6, and PH3960) (
10,
11).
WT lactobacilli were grown at 37°C in MRS broth (Difco,
Detroit, Mich.) containing erythromycin (5 µg/ml) for
NCIMB8826/pMEC4 and NCIMB8826/pMEC127 and chloramphenicol (10
µg/ml) for NCIMB8826/pTG2247, while the Alr
mutants
(MD007 and MD007Int6) required addition of
D-alanine (200 µg/ml)
for growth.
L. lactis WT strains were grown at 30°C in M17
supplemented with 0.5% glucose containing chloramphenicol (5
µg/ml) for NZ3900/pMEC46 and erythromycin (5 µg/ml)
for MG1363/pTX. The Alr
L. lactis PH3960 strain required
addition of
D-alanine (400 µg/ml) for growth. An overnight
culture was used to inoculate fresh medium at a 1:20 dilution,
and cells were grown to the exponential phase (optical density
at 600 nm [OD
600], 1 to 2). For the
L. plantarum and
L. lactis Alr
mutants, alanine starvation was achieved when the
cultures reached an OD
600 of 0.7 by washing the bacteria and
incubating them in medium without
D-alanine for 3 and 2 h, respectively.
The bacterial membrane integrity of the MD007 and PH3960 Alr
mutants was measured at different times during
D-alanine starvation
by using a LIVE/DEAD
Baclight bacterial viability kit (Molecular
Probes, Leiden, The Netherlands). This kit contains a mixture
of two nucleic acid stains, the green fluorescent stain SYTO
9 and the red fluorescent stain propidium iodide (PI). The SYTO
9 stain labels all bacteria in a population, while PI penetrates
only bacteria with damaged membranes, causing a reduction in
the SYTO 9 stain fluorescence when both dyes are present. Cell
samples were diluted to a concentration of approximately 10
6 cells/ml in phosphate-buffered saline (PBS). Equal volumes of
component A (3.34 mM SYTO 9) and component B (20 mM PI) were
prepared extemporaneously, and 3 µl was mixed with each
bacterial suspension and incubated at room temperature in the
dark for 15 min. Flow cytometry analyses were performed with
a FACSCalibur flow cytometer by using the CellQuest software
(Beckton Dickinson, Mountain View, Calif.).
Antigen (inducible promoter) synthesis by the NCIMB8826/pMEC46 strain was induced by addition of 20 ng of nisin (Sigma, St. Louis, Mo.) per ml 1 h after 1:20 dilution of an overnight culture in fresh medium, followed by 4 h of incubation at 37°C. For the mutant MD007Int6/pMEC46 strain, induction was performed for 1 h, and this was followed by 3 h of starvation (as described above) in the presence of nisin (20 ng per ml). For strain NZ3900/pMEC46, antigen production was induced by addition of 5 ng of nisin per ml when the culture reached an OD600 of 0.5 and incubation at 30°C for 3 h. For the mutant PH3960 strain, a 1-h period of induction was followed by 2 h of starvation in the presence of nisin (5 ng per ml). The cells were then pelleted, washed twice in sterile PBS (pH 7.2), and resuspended at a concentration of 1010 CFU per ml in a solution containing 0.2 M sodium bicarbonate, 5% casein hydrolysate, and 0.5% glucose (gavage buffer) for intragastric administration and at a concentration of 1011 CFU per ml in PBS for intravaginal immunization. Production of heterologous antigen (TTFC) was verified by Western blotting after alkaline lysis, as previously described (8).
Immunization and analysis of immune responses.
Animal experiments were performed at an accredited establishment (no. A59107) according to governmental guidelines (no. 86/609/CEE). Eight-week-old female C57BL/6 N Crl BR mice (Charles River Laboratories, St. Aubin-les-Elbeuf, France) were immunized with TTFC-producing WT or mutant L. plantarum or L. lactis strains and control nonexpressing strains. An additional control group received buffer alone. In order to facilitate establishment of the LAB in the vaginas of mice and to synchronize the menstrual cycle of the animals, a hormonal treatment was performed before each administration of bacteria (23). For intravaginal immunization, intraperitoneal injection of medroxyprogesterone acetate (2 mg per mouse; Dépo-provéra; Pharmacia & Upjohn, St. Quentin-Yvelines, France) was performed 5 days before each administration of bacteria. Three consecutive daily doses of 1 x 109 CFU or buffer (100 and 10 µl for intragastric and intravaginal administration, respectively) were administered at 3-week intervals (priming and two or three boosts). Ten days after each administration, serum samples were collected and stored at 20°C until they were used. Mice were sacrificed 10 days after the last boost. For the intragastric experiment, the small intestine of each mouse was removed, opened, and washed with 1 ml of PBS containing a protease inhibitor cocktail (Complete; Boehringer, Mannheim, Germany). Intestinal lavages were clarified by centrifugation at 4,000 x g followed by centrifugation for 10 min at 12,000 x g and 4°C, and the supernatants were collected and stored at 20°C until analysis. The immunoglobulin titers of sera and intestinal fluids were determined by an enzyme-linked immunosorbent assay ELISA as previously described (8). The titer corresponded to the reciprocal of the serum dilution that gave an optical density that was three times the background value. Normalization of the ratio of the TTFC-specific local IgA concentration to the total IgA concentration in intestinal lavages was carried out as previously reported (8). Briefly, the results are expressed as specific activities, which were calculated by dividing the endpoint titer by the total IgA concentration (expressed in micrograms per milliliter) for each lavage.
Statistical analysis.
The results are expressed as means ± standard errors of the means. Statistical significance was evaluated by the Mann-Whitney U test. Differences were considered significant at a P value of <0.05.
Protection assay: determination of TT neutralizing antibody titers in mouse sera.
The toxin neutralization test was performed with the pooled sera of each group of immunized and control mice by using the specifications of the European Pharmacopoeia, with slight modifications. Briefly, mixtures containing serial twofold dilutions of a pool and a definite amount of tetanus toxin (TT) (L+/4,000 level) were injected subcutaneously into two OF1 mice (obtained from the animal facility of the Institut Pasteur de Bruxelles) per mixture. A series of dilutions of a standard antitoxin solution mixed with the same amount of toxin were included in each experiment. The neutralizing antibody content was expressed in international units per milliliter as a range that included the actual value. Due to the small volumes of sera that were available, the detection limit was 0.0025 IU/ml of pooled sera. The protective level of tetanus antitoxin is usually considered to be 0.01 IU/ml (16).

RESULTS
TTFC production by the recombinant strains.
Cell wall mutants with a defective alanine racemase gene (Alr
mutants) have been described for both
L. plantarum NCIMB8826
(
12) and
L. lactis MG1363 (
11). When we compared the WT and
Alr
strains, we observed that the growth of both the
MD007 and PH3960 mutant strains was impaired after
D-alanine
starvation, as expected (Fig.
1A). The bacterial membrane integrity
was further evaluated by flow cytometry by using PI and SYTO
9 staining. Membrane permeability was induced in both mutants
as a function of the
D-alanine starvation time, which resulted
in a maximum number of injured cells after 24 h. In contrast,
the membrane of the WT strains remained largely unaffected,
and less than 10 to 20% of the cells were injured at the end
of the analysis (Fig.
1B). The increased membrane permeability
of the Alr
mutants seemed not to affect their in vivo
persistence in mice, since the viable counts of mutants in feces
were similar to those obtained for their WT counterparts (data
not shown). The plasmid constructs used in this study (Table
1) were introduced by electroporation into the Alr
mutants
of
L. plantarum (MD007, MD007Int6) and
L. lactis (PH3960). The
intracellular levels of TTFC produced by the different recombinant
strains are shown in Fig.
2. Low, medium, and high levels of
antigen (i.e.,

1,

5, and

10% of the total protein content, respectively)
(
7,
25) were produced by
L. plantarum recombinant strains harboring
the expression plasmids pMEC4, pMEC46 (after nisin induction),
and pMEC127, respectively (Fig.
2, lanes 2 to 7). No striking
difference was observed in TTFC production between the corresponding
WT and Alr
mutant strains. The recombinant
L. lactis strains harboring pMEC46 (lanes 9 and 10) produced levels of
TTFC similar to those produced by the
L. plantarum strains carrying
pMEC127 (lanes 6 and 7). These four strains were thus chosen
for comparative immunization with the two LAB vectors. No specific
signal was detected in the control extracts of strains NCIMB8826/pTG2247
and MG1363/pTX (lanes 1 and 8).
Induction of anti-TTFC antibody responses after intragastric immunization.
No significant IgG responses were elicited when mice were immunized
intragastrically with the rWT
L. plantarum strains producing
small (NCIMB8826/pMEC4) or moderate (NCIMB8826Int1/pMEC46) amounts
of TTFC compared to the IgG levels produced by the control groups
(
P < 0.05) (Fig.
3A). In contrast, successful intragastric
immunization was obtained in mice which received the strain
producing higher levels of antigen (NCIMB8826/pMEC127), which
resulted in anti-TTFC IgG mean endpoint titers of 9
x 10
3 and
2.1
x 10
4 after the first and second boosts, respectively. The
response triggered by Alr
mutant MD007/pMEC127 was significantly
greater (
P < 0.05) than that induced by the corresponding
rWT strain, NCIMB8826/pMEC127, and the endpoint titers were
1.3
x 10
5, 1.9
x 10
5, and 4.2
x 10
5 after the first, second,
and third boosts, respectively. A significant response was also
obtained with the mutant MD007Int6/pMEC46 strain, and the mean
endpoint titers were 7.1
x 10
3 and 3.2
x 10
4 after the first
and second boosts, respectively. However, no specific response
was generated by the Alr
MD007/pMEC4 strain. In contrast
to previous experiments conducted with WT strains, including
NCIMB8826/pMEC127, that never allowed induction of detectable
mucosal IgA responses (
7), significant local IgA responses were
observed in the intestinal lavages of mice immunized with the
Alr
mutant strain MD007/pMEC127 compared to the responses
of the control groups (
P < 0.05) (Fig.
3B). The cell wall
defect of the
L. plantarum Alr
mutant thus clearly improved
its efficacy as an oral delivery system. If this resulted from
reduced sequestration of the cytoplasmic antigen TTFC, a similar
mutation in
L. lactis should have led to no improvement as this
strain is known to extensively lyse when it passes through the
gastrointestinal tract (
4). We therefore analyzed the effect
of the
alr mutation in the
L. lactis background. Surprisingly,
as in the case of
L. plantarum, intragastric administration
of the mutant strain of
L. lactis (Alr
PH3960/pMEC46)
led to a significantly enhanced (20- to 30-fold) anti-TTFC IgG
response (mean endpoint titers, 1.8
x 10
4 and 8.9
x 10
4 after
the first and second boosts, respectively) compared to the response
obtained with the recombinant parental strain, NZ3900/pMEC46
(mean endpoint titers, 6.2
x 10
2 and 3.9
x 10
3 after the first
and second boosts, respectively) (Fig.
4A). The response elicited
by the rWT
L. lactis NZ3900/pMEC46 strain was significantly
(
P < 0.05) less than the response elicited by the rWT
L. plantarum NCIMB8826/pMEC127 strain even though both strains
produced equivalent amounts of antigen in vitro (Fig.
2, lanes
6 and 9). No difference in the isotypic profiles was observed
for the WT and mutant strains. The dominant anti-TTFC antibody
isotypes induced by all bacterial carriers were IgG1, IgG2b,
and, to a lesser extent, IgG2a (Fig.
4B), which corroborates
previous observations (
7,
8). No serum IgA was detected.
Protective capacity of the anti-TTFC serum antibodies of intragastrically immunized mice.
Protection was evaluated by measuring the ability of elicited
serum antibodies to neutralize TT, an assay whose results have
been proven to correlate well with the results obtained after
a direct lethal challenge with TT (
8). Notably, protective levels
of anti-TT antibodies were induced by both recombinant Alr
mutant strains, MD007/pMEC127 and PH3960/pMEC46. In the case
of the WT strains, only
L. plantarum strain NCIMB8826/pMEC127
was found to induce neutralizing antibodies at levels above
the protective limit, in contrast to
L. lactis strain NZ3900/pMEC46
(Table
2).
Induction of anti-TTFC antibody responses after intravaginal immunization.
To evaluate if the improved performance of the mutant strains
as antigen delivery systems was restricted to the gastrointestinal
tract, we compared the immunogenicities of the four recombinant
strains using the vaginal route of delivery. We first optimized
the mouse hormonal treatment by comparing the effects of administration
of progesterone and estrogen to the effect of no hormone administration.
The two latter regimens did not allow induction of a detectable
and reproducible immune response after vaginal administration
of the rWT
L. plantarum NCIMB8826/pMEC127 strain, and the estrogen
treatment led to a notable thickening of the vaginal epithelium
(data not shown). In contrast, after progesterone treatment
a remarkably high anti-TTFC humoral IgG response was elicited
by intravaginal administration of the
L. plantarum NCIMB8826/pMEC127
strain, and the mean endpoint titer was 8.9
x 10
3 after the
second boost (Fig.
5). Moreover, as observed for the oral route,
the use of the Alr
strain MD007/pMEC127 significantly
enhanced the IgG response, particularly at the priming level.
The response elicited by the rWT
L. lactis NZ3900/pMEC46 strain
was significantly less than the response obtained with the rWT
lactobacilli. Administration of the Alr
mutant PH3960/pMEC46
strain led to a significantly enhanced response; however, the
IgG level remained close to the IgG level induced with the rWT
lactobacilli.

DISCUSSION
The ability of recombinant LAB to act as efficient live vaccines
has been best demonstrated by systemic and intranasal routes
using TTFC as a model antigen (
8,
21,
28). In our hands, comparative
studies conducted with
L. plantarum and
L. lactis producing
TTFC intracellularly demonstrated that the former organism was
more immunogenic than the latter when mice were immunized by
the intragastric route. The greater resistance of
L. plantarum to the gastric environment and its better survival in the gastrointestinal
tract might explain this observation, yet this property could
also lead to limited in vivo release of bioactive molecules.
Therefore, we investigated whether the potential of
L. plantarum as a live delivery system could be improved by using a mutant
having a more permeable cell envelope. A similar mutant constructed
in a
L. lactis background, which is intrinsically more susceptible
to lysis, was expected to be a less effective vaccine vehicle.
Surprisingly, both
L. plantarum and
L. lactis Alr
mutants
producing TTFC intracellularly turned out to be far more immunogenic
by the intragastric route than their WT counterparts. As mentioned
above, successful intragastric immunization is highly dependent
on the antigen dose delivered by the recombinant LAB. When the
Alr
mutants were used as carriers, the anti-TTFC immune
responses induced were significantly higher than those induced
by the WT vectors (Fig.
3A and
4A). In our hands, although both
the WT and mutant strains of
L. plantarum elicited protective
immune responses, only the recombinant Alr
mutant of
L. lactis led to protective neutralizing antibody titers. Even
when the antigen dose did not seem to be limiting, as in the
case of the rWT strain
L. plantarum NCIMB8826/pMEC127, the specific
serum IgG levels were higher after immunization with the Alr
mutant MD007/pMEC127. Notably, while no serum IgA was detected,
significant levels of intestinal TTFC-specific IgA were observed
only after intragastric administration of the mutant
L. plantarum carrier. As shown by flow cytometry with bacterial viability
dyes, both the MD007 and PH3960 Alr
mutants were much
more permeable than their rWT counterparts. It is thus tempting
to propose that increased in vivo delivery of the antigen plays
a major role in the effect observed, even though the possibility
of better antigen presentation to immune cells cannot be excluded.
The mutant Alr
strains were indeed shown to release larger
amounts of cytoplasmic enzymes, at least in vitro (
22a). We
also compared the immunogenicities of the four recombinant strains
producing TTFC by the vaginal route. The vaginal and gastrointestinal
mucosae differ substantially in terms of the nature of the associated
antigen-presenting cells and in structure; the former is a stratified
epithelium, while the latter is a single-cell layer (
20). Both
rWT LAB strains were able to induce significant humoral IgG
responses by the vaginal route after an optimized hormonal treatment,
and the immunogenicity of the rWT lactobacilli was greater than
that of the rWT lactococci in this case. These results are quite
remarkable, as the vagina is generally not considered a potent
immune inductive site in mice. As observed for intragastric
immunization, the use of Alr
mutants led to dramatic
enhancement of the serum antibody titers for both LAB strains.
The IgG titers (endpoint titers, >10
4) obtained with the
MD007 and PH3960 Alr
mutants reached levels similar to
those shown to be protective after nasal administration (
8)
and oral administration (
7). We thus speculate that vaginal
immunization with these vectors could confer protection against
TT. We recently confirmed the performance of the Alr
mutant of
L. plantarum as a mucosal antigen carrier in a
Helicobacter felis infection mouse model. Notably, significant protection
was induced after intragastric administration of the recombinant
mutant strain producing the weakly immunogenic urease B subunit,
an effect not exhibited by the corresponding recombinant WT
strain (B. Corthesy et al., unpublished data). Altogether, our
results demonstrate that the Alr
mutants allow substantially
improved antigen presentation to the immune system. This might
not be solely linked to increased leakage of TTFC in vivo but
could be a consequence of better antigen presentation by recombinant
LAB. Soluble antigens are known to be less immunogenic than
particulate or replicative antigens, especially when mucosal
routes are used. Moreover, Corinti et al. (
2) demonstrated that
dendritic cells pulsed with recombinant LAB engineered for cell
surface exposure of TTFC were more efficient at stimulating
specific CD4
+ T cells than dendritic cells incubated with soluble
TTFC mixed with nonrecombinant bacterial cells. Finally, we
cannot rule out the possibility that the cell wall modifications
induced by inactivation of the
alr gene also affect the cross
talk between the bacterial strain and the host. Taken together,
our results demonstrate that the Alr
mutants described
here constitute a substantially improved antigen delivery system
for different mucosal routes. In addition, these and other cell
wall mutant strains might help unravel the complex mechanisms
underlying commensal bacterium-host interactions.

ACKNOWLEDGMENTS
This work was supported by grants EU BIO4-CT96-0542 and EU QLK3-2000-00340
and by the Institut Pasteur de Lille and the Institut Pasteur
de Bruxelles.
We are grateful to E. Van Nerom and F. Tweepenninckx for their skillful help with protection experiments. We warmly thank S. Pavan for providing strain MD007Int6 and B. Corthesy for critical reading of the manuscript. E. Sablon, Innogenetics N.V., Zwijnaarde, Belgium, kindly supplied rabbit anti-TTFC antibodies.

FOOTNOTES
* Corresponding author Mailing address: Laboratoire de Bactériologie des Ecosystèmes, Institut Pasteur de Lille, 1, rue du Pr Calmette, B.P. 245, F-59019 Lille Cedex, France. Phone: (33) 320-87-11-88. Fax: (33) 320-87-11-92. E-mail:
corinne.grangette{at}ibl.fr.

Editor: J. N. Weiser
Present address: Nutrition and Health Department, Nestle Research Centre, CH 1000 Lausanne, Switzerland. 

REFERENCES
1 - Chatfield, S. N., I. G. Charles, A. J. Makoff, M. D. Oxer, G. Dougan, D. Pickard, D. Slater, and N. F. Fairweather. 1992. Use of the nirB promoter to direct the stable expression of heterologous antigens in Salmonella oral vaccine strains: development of a single-dose oral tetanus toxin vaccine. Bio/Technology 10:888-892.[CrossRef][Medline]
2 - Corinti, S., D. Medaglini, A. Cavani, M. Rescigno, G. Pozzi, P. Ricciardi-Castagnoli, and G. Girolomoni. 1999. Human dendritic cells very efficiently present a heterologous antigen expressed on the surface of recombinant gram-positive bacteria to CD4+ T lymphocytes. J. Immunol. 163:3029-3036.[Abstract/Free Full Text]
3 - de Ruyter, P. G., O. P. Kuipers, and W. M. de Vos. 1996. Controlled gene expression systems for Lactococcus lactis with the food-grade inducer nisin. Appl. Environ. Microbiol. 62:3662-3667.[Abstract]
4 - Drouault, S., G. Corthier, S. D. Ehrlich, and P. Renault. 1999. Survival, physiology, and lysis of Lactococcus lactis in the digestive tract. Appl. Environ. Microbiol. 65:4881-4886.[Abstract/Free Full Text]
5 - Dunstan, S. J., C. P. Simmons, and R. A. Strugnell. 1998. Comparison of the abilities of different attenuated Salmonella typhimurium strains to elicit humoral immune responses against a heterologous antigen. Behring Inst. Mitt. 98:732-740.
6 - Gasson, M. J. 1983. Plasmid complements of Streptococcus lactis NCDO 712 and other lactic streptococci after protoplast inducing curing. J. Bacteriol. 154:1-9.[Abstract/Free Full Text]
7 - Grangette, C., H. Muller-Alouf, M. Geoffroy, D. Goudercourt, M. Turneer, and A. Mercenier. 2002. Protection against tetanus toxin after intragastric administration of two recombinant lactic acid bacteria: impact of strain viability and in vivo persistence. Vaccine 20:3304-3309.[CrossRef][Medline]
8 - Grangette, C., H. Müller-Alouf, D. Goudercourt, M.-C. Geoffroy, M. Turneer, and A. Mercenier. 2001. Mucosal immune responses and protection against tetanus toxin after intranasal immunization with recombinant Lactobacillus plantarum. Infect. Immun. 69:1547-1553.[Abstract/Free Full Text]
9 - Heaton, M. P., R. B. Johnston, and T. L. Thompson. 1988. Controlled lysis of bacterial cells utilizing mutants with defective synthesis of D-alanine. Can. J. Microbiol. 34:256-261.[Medline]
10 - Hols, P., C. Defrenne, T. Ferain, S. Derzelle, B. Delplace, and J. Delcour. 1997. The alanine racemase gene is essential for growth of Lactobacillus plantarum. J. Bacteriol. 179:3804-3807.[Abstract/Free Full Text]
11 - Hols, P., M. Kleerebezem, A. N. Schanck, T. Ferain, J. Hugenholz, J. Delcour, and W. M. de Vos. 1999. Conversion of Lactococcus lactis from homolactic to homoalanine fermentation through metabolic engineering. Nat. Biotechnol. 17:588-592.[CrossRef][Medline]
12 - Hols, P., P. Slos, P. Dutot, J. Reymund, P. Chabot, B. Delplace, J. Delcour, and A. Mercenier. 1997. Efficient secretion of the model antigen M6-gp41E in Lactobacillus plantarum NCIMB 8826. Microbiology 143:2733-2741.[Abstract/Free Full Text]
13 - Jacobs, W. R., S. B. Snapper, L. Lugosi, and B. R. Bloom. 1990. Development of BCG as recombinant vaccine delivery vehicle. Curr. Top. Microbiol. Immunol. 155:153-160.[Medline]
14 - Klijn, N., A. H. Weerkamp, and W. M. de Vos. 1995. Genetic marking of Lactococcus lactis shows its survival in the human gastrointestinal tract. Appl. Environ. Microbiol. 61:2771-2774.[Abstract]
15 - Kremer, L., L. Dupré, G. Riveau, A. Capron, and C. Locht. 1998. Systemic and mucosal immune responses after intranasal administration of recombinant Mycobacterium bovis Bacillus Calmette-Guérin expressing gluthathione S-transferase from Schistosoma haematobium. Infect. Immun. 66:5669-5676.[Abstract/Free Full Text]
16 - McComb, J. A. 1964. The prophylactic dose of homologous tetanus antitoxin. N. Engl. J. Med. 270:175-178.
17 - Medaglini, D., A. Ciabattini, M. R. Spinosa, T. Maggi, H. Marcotte, M. R. Oggioni, and G. Pozzi. 2001. Immunization with recombinant. Streptococcus gordonii expressing tetanus toxin fragment C confers protection from lethal challenge in mice. Vaccine 19:1931-1939.[CrossRef][Medline]
18 - Medaglini, D., C. M. Rush, P. Sestini, and G. Pozzi. 1997. Commensal bacteria as vectors for mucosal vaccines against sexually transmitted diseases: vaginal colonization with recombinant streptococci induces local and systemic antibodies in mice. Vaccine 15:1330-1337.[CrossRef][Medline]
19 - Mielcarek, N., J. Cornette, A. M. Schacht, R. J. Pierce, C. Locht, A. Capron, and G. Riveau. 1997. Intranasal priming with recombinant Bordetella pertussis for the induction of a systemic immune response against a heterologous antigen. Infect. Immun. 65:544-550.[Abstract]
20 - Neutra, M. R., E. Pringault, and J. P. Kraehenbuhl. 1996. Antigen sampling across epithelial barriers and induction of mucosal immune responses. Annu. Rev. Immunol. 14:275-300.[CrossRef][Medline]
21 - Norton, P. M., J. M. Wells, H. W. G. Brown, A. M. Macpherson, and R. W. F. Le Page. 1997. Protection against tetanus toxin in mice nasally immunized with recombinant Lactococcus lactis expressing tetanus toxin fragment C. Vaccine 15:616-619.[CrossRef][Medline]
22 - Ntamere, A. S., D. J. Taron, and F. C. Neuhaus. 1987. Assembly of D-alanyl-lipoteichoic acid in Lactobacillus casei: mutants deficient in the D-alanyl ester content of this amphiphile. J. Bacteriol. 169:1702-1711.[Abstract/Free Full Text]
22 - Palumbo, E., C. Favier, M. Deghorain, P. S. Cocconcelli, C. Grangette, A. Mercenier, E. Vaughan, and P. Hols. 2004. Knockout of the alanine racemase gene in Lactobacillus plantarum results in septation defects and cell wall perforation. FEMS Microbiol. Lett. 233:131-138.[CrossRef][Medline]
23 - Parr, M. B., and E. L. Parr. 1990. Antigen recognition in the female reproductive tract. I. Uptake of intraluminal protein tracers in the mouse vagina. J. Reprod. Immunol. 17:101-114.[CrossRef][Medline]
24 - Pavan, S., P. Hols, J. Delcour, M. C. Geoffroy, C. Grangette, M. Kleerebezem, and A. Mercenier. 2000. Adaptation of the nisin-controlled expression system in Lactobacillus plantarum: a tool to study in vivo biological effects. Appl. Environ. Microbiol. 66:4427-4432.[Abstract/Free Full Text]
25 - Reveneau, N., M.-C. Geoffroy, C. Locht, P. Chagnaud, and A. Mercenier. 2001. Comparison of the immune responses induced by local immunizations with recombinant Lactobacillus plantarum producing tetanus toxin fragment C in different cellular locations. Vaccine 20:1769-1777.
26 - Robinson, K., L. M. Chamberlain, K. M. Schofield, J. M. Wells, and R. W. F. Le Page. 1997. Oral vaccination of mice against tetanus with recombinant Lactococcus lactis. Nat. Biotechnol. 15:653-657.[CrossRef][Medline]
27 - Ryan, E. T., J. R. Butterton, R. Neal Smith, P. A. Carroll, T. I. Crean, and S. B. Calderwood. 1997. Protective immunity against Clostridium difficile toxin a induced by oral immunization with a live, attenuated Vibrio cholerae vector strain. Infect. Immun. 65:2941-2949.[Abstract]
28 - Shaw, D. M., B. Gaerthé, R. J. Leer, J. G. M. M. Van Der Stap, C. Smittenaar, M.-J. Heijne den Bak-Glashouwer, J. E. R. Thole, F. J. Tielen, P. H. Pouwels, and C. E. G. Havenith. 2000. Engineering the microflora to vaccinate the mucosa: serum immunoglobulin G responses and activated draining cervical lymph nodes following mucosal application of tetanus toxin fragment C-expressing lactobacilli. Immunology 100:510-518.[CrossRef][Medline]
29 - Thapar, M. A., E. L. Parr, and M. B. Parr. 1990. The effect of adjuvants on antibody titers in mouse vaginal fluid after intravaginal immunization. J. Reprod. Immunol. 17:207-216.[CrossRef][Medline]
30 - Vesa, T., P. Pochart, and P. Marteau. 2000. Pharmacokinetics of Lactobacillus plantarum NCIMB 8826, Lactobacillus fermentum KLD, and Lactococcus lactis MG 1363 in the human gastrointestinal tract. Aliment. Pharmacol. Ther. 14:823-828.[CrossRef][Medline]
Infection and Immunity, May 2004, p. 2731-2737, Vol. 72, No. 5
0019-9567/04/$08.00+0 DOI: 10.1128/IAI.72.5.2731-2737.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Meyrand, M., Boughammoura, A., Courtin, P., Mezange, C., Guillot, A., Chapot-Chartier, M.-P.
(2007). Peptidoglycan N-acetylglucosamine deacetylation decreases autolysis in Lactococcus lactis. Microbiology
153: 3275-3285
[Abstract]
[Full Text]
-
Corthesy, B., Gaskins, H. R., Mercenier, A.
(2007). Cross-Talk between Probiotic Bacteria and the Host Immune System. J. Nutr.
137: 781S-790S
[Abstract]
[Full Text]
-
Steen, A., Palumbo, E., Deghorain, M., Cocconcelli, P. S., Delcour, J., Kuipers, O. P., Kok, J., Buist, G., Hols, P.
(2005). Autolysis of Lactococcus lactis Is Increased upon D-Alanine Depletion of Peptidoglycan and Lipoteichoic Acids. J. Bacteriol.
187: 114-124
[Abstract]
[Full Text]